Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

WILMINGTON, Del.--(BUSINESS WIRE)--Aug 1, 2023--

Related Keywords

Canada ,Austria ,Germany ,Norway ,United States ,Turkey ,United Kingdom ,France ,Israel ,Delaware ,Japan ,Switzerland ,Russia ,American ,Ruxolitinib Jakavi ,Baricitinib Olumiant ,Retifanlimab Zynyz ,Dashyant Dhanak ,July Incyte ,Greg Shertzer ,Catalina Loveman ,Pemigatinib Pemazyre ,Tafasitamab Monjuvi ,Ponatinib Iclusig ,Capmatinib Tabrecta ,Syndax Pharmaceuticals ,Takeda Pharmaceuticals International ,Millennium Pharmaceuticals Inc ,Macrogenics Inc ,Novartis ,American Society Of Clinical Oncology ,Xencor Inc ,Drug Administration ,Early Access Program ,Pharmaceuticals Inc ,Replimune Group Inc ,Takeda Pharmaceutical Company ,Incyte Corporation ,Us Food Drug Administration ,Cellenkos Inc ,European Union ,Exchange Commission ,Chief Executive Officer ,American Society ,Clinical Oncology ,Pivotal Phase ,Replimune Group ,Global Assessment Treatment Success ,Three Phase ,Two Phase ,License Agreement ,Chief Scientific Officer ,Investigational New Drug ,Quarter Financial ,Accepted Accounting Principles ,Royalty Revenues Product ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Medicinal Product ,Millennium Pharmaceuticals ,Condensed Consolidated Statements ,Business Wire ,Business ,Ews Ap ,